Because eRMS is one of the three major tumor types that develop in Ptch1+/− mutant mice [72] and the other two tumor types (BCC and medulloblastoma) have shown response to SMO inhibition in vivo [73], it was assumed that targeting the Hedgehog pathway would have utility in eRMS. This evidence concerns the gene PTCH1 and medulloblastoma.